- Home
- GOF vs BCRX Comparison
GOF vs BCRX Comparison
Compare GOF & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | BCRX |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2006 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GOF | BCRX |
|---|---|---|
| Price | $10.77 | $9.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 1.5M | ★ 6.5M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.50 | $6.00 |
| 52 Week High | $15.20 | $11.22 |
Technical Indicators
Market Signals| Indicator | GOF | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 47.36 |
| Support Level | $10.54 | $8.13 |
| Resistance Level | $11.02 | $9.61 |
| Average True Range (ATR) | 0.11 | 0.61 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 51.06 | 14.88 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.